This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Destiny Pharma Toekomstige groei

Future criteriumcontroles 0/6

Destiny Pharma's revenue and earnings are forecast to decline at 171.4% and 15.5% per annum respectively while EPS is expected to decline by 13.6% per annum.

Belangrijke informatie

-15.5%

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei35.6%
Inkomstengroei-171.4%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt15 Jul 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:D89 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2025N/A-8N/AN/A1
12/31/2024N/A-6-6-52
12/31/20231-6-6-5N/A
9/30/20231-6-5-5N/A
6/30/20231-6-5-5N/A
3/31/20231-6-6-6N/A
12/31/20220-7-6-6N/A
9/30/20220-6-5-5N/A
6/30/20220-6-5-5N/A
3/31/20220-6-5-5N/A
12/31/20210-5-5-5N/A
9/30/20210-5-7-6N/A
6/30/20210-5-9-6N/A
3/31/20210-5-8-6N/A
12/31/20200-5-8-5N/A
9/30/20200-5-6-5N/A
6/30/20200-5-4-4N/A
3/31/20200-5-4-4N/A
12/31/20190-5-5-5N/A
9/30/20190-5-5-5N/A
6/30/2019N/A-5-6-6N/A
3/31/2019N/A-5-5-5N/A
12/31/2018N/A-5-5-5N/A
9/30/2018N/A-5-4-4N/A
6/30/2018N/A-4-3-3N/A
3/31/2018N/A-4-3-3N/A
12/31/2017N/A-3-2-2N/A
9/30/2017N/A-2N/A-2N/A
6/30/2017N/A-2N/A-1N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A-1N/A-1N/A
12/31/2015N/A-1N/A-1N/A
12/31/2014N/A-2N/A-2N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: D89 is forecast to remain unprofitable over the next 3 years.

Winst versus markt: D89 is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: D89 is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: D89 is forecast to have no revenue next year.

Hoge groei-inkomsten: D89 is forecast to have no revenue next year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if D89's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven